The Urgent Need for Reliable Cell Models in ALS Drug Development

Published on June 25, 2024
motor neuron

Amyotrophic lateral sclerosis (ALS) is a relentless neurodegenerative disease that has eluded effective treatment for over a century. Recent high-profile failures in ALS drug trials highlight a critical gap in the drug development process: the need for more reliable cell models to better predict clinical outcomes.

Continue reading on website
Other news

U.S. Anesthesia Partners Launches USAP4USAP, a 501(c)3 Nonprofit Dedicated to Helping USAP Team Members in Need

June 21, 2024
U.S. Anesthesia Partners Launches USAP4USAP, a 501(c)3 Nonprofit Dedicated to Helping USAP Team Members in Need Jodi_Lewis Fri, 06/21/2024 - 09:41 Read more about U.S. Anesthesia Partners Launches USAP4USAP, a 501(c)3 Nonprofit Dedicated to Helping USAP Team Members in Need

BioPharm International: Optimizing Cell Line Development for Next Generation Biologics

June 26, 2024
BioPharm International’s June 2024 issue features our VP of Cell Line Development, Simon Keen, discussing how improving the flexibility of cell line development through the utilization of platform approaches and suitable partnerships can reduce potential bottlenecks in the development pathway of novel biologics.To rapidly develop the next generation of biological therapeutics, cell line developers